Last reviewed · How we verify
Rifapentine and Isoniazid for 3 months
Rifapentine and Isoniazid for 3 months is a Small molecule drug developed by Taichung Veterans General Hospital. It is currently FDA-approved. Also known as: 3HP, Priftin, Isoniazid.
Rifapentine and Isoniazid for 3 months, developed by Taichung Veterans General Hospital, is a marketed combination therapy for an unspecified primary indication. The key composition patent expires in 2028, providing a period of exclusivity and potential revenue protection. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit market visibility and investor confidence.
At a glance
| Generic name | Rifapentine and Isoniazid for 3 months |
|---|---|
| Also known as | 3HP, Priftin, Isoniazid |
| Sponsor | Taichung Veterans General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2, PHASE3)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- One-month Latent Tuberculosis Treatment for Renal Transplant Candidates (PHASE4)
- TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts (PHASE3)
- Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients (PHASE4)
- Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV (PHASE1, PHASE2)
- 1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam (PHASE3)
- Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifapentine and Isoniazid for 3 months CI brief — competitive landscape report
- Rifapentine and Isoniazid for 3 months updates RSS · CI watch RSS
- Taichung Veterans General Hospital portfolio CI
Frequently asked questions about Rifapentine and Isoniazid for 3 months
What is Rifapentine and Isoniazid for 3 months?
Who makes Rifapentine and Isoniazid for 3 months?
Is Rifapentine and Isoniazid for 3 months also known as anything else?
What development phase is Rifapentine and Isoniazid for 3 months in?
Related
- Manufacturer: Taichung Veterans General Hospital — full pipeline
- Also known as: 3HP, Priftin, Isoniazid
- Compare: Rifapentine and Isoniazid for 3 months vs similar drugs
- Pricing: Rifapentine and Isoniazid for 3 months cost, discount & access